S24.159S Insurance Policy Changes

ICD-10 S24.159S is officially defined as "Other incomplete lesion at unspecified level of thoracic spinal cord, sequela." code S24.159S is referenced in 5 tracked payer policy changes from Aetna. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code S24.159S is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 4, 2026Medium impact
Autologous Skeletal Myoblast/Mononuclear Bone Marrow Cell Transplantation (CPB 0599, reviewed 2026-09-18)
Autologous skeletal myoblast transplantation, intra-coronary and intra-myocardial autologous bone marrow cell transplantation, and intra-arterial or intra-muscular autologous mononuclear bone marrow cell transplantation are considered experimental, investigational, or unproven because effectiveness has not been established. Autologous or allogeneic bone marrow-derived mesenchymal stem cell transplantation is likewise considered experimental, investigational, or unproven for conditions including acute myocardial infarction, diabetes, multiple sclerosis, knee osteoarthritis, spinal cord injury, rheumatoid arthritis, Crohn's disease, and peripheral nerve repair. CPT codes 0263T, 0264T, 0265T, 38240, and 38241 and HCPCS code C9782 are listed as not covered for the listed indications, and the ICD-10 codes for those indications are listed as not covered for these services.
Aetna · Identified Aug 19, 2026Medium impact
Mechanical Stretching Devices for Contracture and Joint Stiffness (CPB 0405, reviewed 2026-06-30)
Aetna covers dynamic splinting devices for the knee, elbow, wrist, finger or toe when there are documented signs and symptoms of significant motion stiffness or loss and the splint is used as an adjunct to occupational or physical therapy at least 3 weeks after injury or surgery, or when the member has a documented history of motion loss in a joint and is in the acute post-operative period after a second or subsequent surgery. The policy also covers the dynamic adjustable ankle extension/flexion device (e.g., JAS Ankle) for contractures, the EZ Turnbuckle orthosis after open reduction internal fixation for radial head fracture, and continued mechanical stretching when documented improvement in range of motion is shown. Dynamic splinting for carpal tunnel syndrome, cerebral palsy, foot drop associated with neuromuscular diseases, multiple sclerosis, stroke and plantar fasciitis, JAS splints, PASS devices such as the ERMI flexionators and extensionators, SaeboMas, Medi-Dyne Prostretch, and mechanical stretching for skin graft contracture are considered experimental, investigational or unproven.
Aetna · Identified Aug 19, 2026Medium impact
Zoledronic Acid (CPB 0524, reviewed 2026-02-12)
Aetna's clinical policy bulletin covers zoledronic acid for commercial medical plans. Zoledronic acid 5 mg (Reclast or generic) is considered medically necessary for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, Paget's disease of bone, and treatment-related bone loss in men with prostate cancer receiving androgen deprivation therapy, when the listed criteria are met. Zoledronic acid 4 mg (formerly branded Zometa) is considered medically necessary for bone metastases from a solid tumor, certain breast cancer indications, hypercalcemia of malignancy, Langerhans cell histiocytosis with bone disease, multiple myeloma, and systemic mastocytosis with osteopenia or osteoporosis. Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Hospitalization for the Initiation of Ketogenic Diet (CPB 0226, reviewed 2026-04-23)
Aetna considers hospitalization for initiation of a ketogenic diet medically necessary for intractable seizures, including Doose syndrome and Lennox-Gastaut syndrome, when all listed selection criteria are met, and for persons with glucose transporter protein type 1 deficiency or pyruvate dehydrogenase complex deficiency. Aetna considers hospitalization for initiation of a ketogenic diet of unproven value for all other indications, including adult super-refractory status epilepticus, Alzheimer's disease, autism spectrum disorder, cancer, migraine prevention, multiple sclerosis, Parkinson's disease, schizophrenia and type 2 diabetes. Hospitalization for initiation of the Atkins diet for intractable seizures, mitochondrial diseases, or other indications is considered experimental, investigational, or unproven.
Aetna · Identified Aug 15, 2026Medium impact
Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)
Aetna considers quantitative EEG (brain mapping, also called BEAM) medically necessary only as an adjunct to traditional EEG for specified uses, including ambulatory EEG recording to facilitate later expert visual interpretation, continuous EEG monitoring by frequency-trending in the operating room or ICU, and topographic voltage and dipole analysis in pre-surgical evaluations for intractable epilepsy. Aetna considers quantitative EEG experimental, investigational or unproven for all other indications, including attention disorders, autism spectrum disorders, depression, schizophrenia, bipolar disorder, insomnia, fibromyalgia, post-traumatic stress disorder and post-concussion syndrome. The BrainScope One System (Ahead 300) is considered experimental, investigational or unproven for evaluation of concussion or traumatic brain injury.

Watch S24.159S

Get one email when a payer policy names S24.159S, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code S24.159S?

There are 5 tracked policy changes affecting code S24.159S, including updates from Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code S24.159S?

Payers that have issued tracked updates for code S24.159S include: Aetna.

How do I get notified when code S24.159S policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code S24.159S. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code S24.159S?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Autologous Skeletal Myoblast/Mononuclear Bone Marrow Cell Transplantation (CPB 0599, reviewed 2026-09-18)

Mechanical Stretching Devices for Contracture and Joint Stiffness (CPB 0405, reviewed 2026-06-30)

Zoledronic Acid (CPB 0524, reviewed 2026-02-12)

Hospitalization for the Initiation of Ketogenic Diet (CPB 0226, reviewed 2026-04-23)

Quantitative EEG (Brain Mapping) (CPB 0221, reviewed 2026-04-14)

What insurance policy changes affect code S24.159S?

Which payers have updated policy for code S24.159S?

How do I get notified when code S24.159S policy changes?

Why do payers change policies for code S24.159S?